Fulgent Genetics Stock Drops Below 50-Day Moving Average

Analysts Divided on Biotech Firm's Outlook After Share Price Decline

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) fell below their 50-day moving average on Monday, sparking concerns among investors. The California-based genetic testing company has seen its stock price decline in recent weeks, with analysts issuing mixed ratings on the company's prospects.

Why it matters

Fulgent Genetics is a prominent player in the genetic testing and diagnostics industry, providing a range of services including hereditary cancer panels, rare disease testing, and COVID-19 diagnostics. The company's stock performance is closely watched by investors as an indicator of its financial health and market position.

The details

Fulgent Genetics' stock price dropped to as low as $14.79 on Monday, crossing below its 50-day moving average of $23.00. Several equity analysts have recently commented on the company's shares, with Wall Street Zen downgrading the stock to a 'sell' rating and Zacks Research moving it from a 'strong-buy' to a 'hold' rating. The company's latest quarterly earnings report, released in late February, showed mixed results, with revenue falling short of analyst estimates.

  • Fulgent Genetics' stock price crossed below its 50-day moving average on Monday, March 16, 2026.
  • The company released its latest quarterly earnings report on Friday, February 27, 2026.

The players

Fulgent Genetics, Inc.

A California-based company specializing in high-complexity genetic testing and diagnostic services, operating CAP- and CLIA-certified laboratories and leveraging next-generation sequencing technologies.

Wall Street Zen

An equity research firm that recently downgraded Fulgent Genetics' stock to a 'sell' rating.

Zacks Research

An equity research firm that recently moved Fulgent Genetics' stock rating from 'strong-buy' to 'hold'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Fulgent Genetics' stock performance is a closely watched indicator in the genetic testing industry, and the company's recent decline below its 50-day moving average has raised concerns among investors. The mixed analyst ratings and earnings results suggest the company's outlook remains uncertain, highlighting the need for continued monitoring of its financial and operational performance.